These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8791770)

  • 1. Assays of omeprazole metabolism as a substrate probe for human CYP isoforms.
    Birkett DJ; Andersson T; Miners JO
    Methods Enzymol; 1996; 272():132-9. PubMed ID: 8791770
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.
    Katsuki H; Hamada A; Nakamura C; Arimori K; Nakano M
    Eur J Clin Pharmacol; 2001 Dec; 57(10):709-15. PubMed ID: 11829200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
    Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
    Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.
    Naritomi Y; Terashita S; Kagayama A
    Xenobiotica; 2004 May; 34(5):415-27. PubMed ID: 15370958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
    Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
    J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro measurement of CYP2C19 activity.
    Wedlund PJ; Wilkinson GR
    Methods Enzymol; 1996; 272():105-14. PubMed ID: 8791767
    [No Abstract]   [Full Text] [Related]  

  • 8. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
    Shu Y; Wang LS; Xu ZH; He N; Xiao WM; Wang W; Huang SL; Zhou HH
    J Pharmacol Exp Ther; 2000 Nov; 295(2):844-51. PubMed ID: 11046127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug interactions with proton pump inhibitors.
    Unge P; Andersson T
    Drug Saf; 1997 Mar; 16(3):171-9. PubMed ID: 9098655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
    Rost KL; Roots I
    Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
    Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
    Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
    Abelö A; Andersson TB; Antonsson M; Naudot AK; Skånberg I; Weidolf L
    Drug Metab Dispos; 2000 Aug; 28(8):966-72. PubMed ID: 10901708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.
    Funck-Brentano C; Becquemont L; Lenevu A; Roux A; Jaillon P; Beaune P
    J Pharmacol Exp Ther; 1997 Feb; 280(2):730-8. PubMed ID: 9023285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone.
    Shu Y; Wang LS; Xiao WM; Wang W; Huang SL; Zhou HH
    Acta Pharmacol Sin; 2000 Aug; 21(8):753-8. PubMed ID: 11501187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes.
    Lewis DF; Lake BG
    Toxicology; 1998 Jan; 125(1):31-44. PubMed ID: 9585098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between omeprazole hydroxylase and CYP2C19 genotype in North Indians.
    Lamba JK; Dhiman RK; Singh R; Kohli KK
    Eur J Clin Pharmacol; 2001 Nov; 57(9):649-52. PubMed ID: 11791894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional discussions regarding the altered metabolism and transport of omeprazole after long-term use of St John's wort.
    Xie HG
    Clin Pharmacol Ther; 2005 Oct; 78(4):440-1. PubMed ID: 16198664
    [No Abstract]   [Full Text] [Related]  

  • 19. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
    Tassaneeyakul W; Vannaprasaht S; Yamazoe Y
    Br J Clin Pharmacol; 2000 Feb; 49(2):139-44. PubMed ID: 10671908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans.
    Gonzalez HM; Romero EM; Peregrina AA; de J Chávez T; Escobar-Islas E; Lozano F; Hoyo-Vadillo C
    J Clin Pharmacol; 2003 Nov; 43(11):1211-5. PubMed ID: 14551175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.